11 results
To evaluate safety of 3-months versus standard 12-months of DAPT
The effect of pulse rate on temporal resolution and speech intelligibility in cochlear implant users
To determine the (in)direct effect of CI pulse rate on speech intelligibility by means of (1) a standard test for temporal resolution: amplitude modulation detection (AMD) at two different modulation frequencies, (2) speech intelligibility tests (…
Ticagrelor, at steady state (i.e. after 30 days), will be associated to an improved endothelial function as compared to clopidogrel or prasugrel.
There are four main objectives in this research project, belonging to two different parts of the study. Part 1 comprises objectives 1 and 2:1. Determine the electrode discrimination abilities of prelingually deafened adult CI users in order to…
Primary:To evaluate the probability that FNA successfully obtains liver tissue specimens from which to evaluate liver drug concentrationsSecondary:1. To characterize the steady-state hepatic pharmacokinetics of MK-7009 (e.g., area under the liver…
To determine if ticagrelor at treatment steady state will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients.
Primary Objectives:1. To compare the magnitude of baseline (or intrinsic) platelet reactivity between T2DM patients and healthy volunteers using multiple platelet function assays 2. To compare the magnitude of baseline (or intrinsic) platelet…
To assess the efficacy, safety and cost-effectiveness of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel or prasugrel/ticagrelor.
To assess the safety, efficacy and net clinical benefit of clopidogrel versus the new antiplatelet drugs i.e. ticagrelor and prasugrel in patients older than 70 years.
To determine if clopidogrel treatment can be optimized in patients with a low or high BW/BMI compared to patients with a normal BW by adjusting the dosage of clopidogrel and evaluating platelet reactivity measured using the VerifyNow.
The primary objective of this study is to assess the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after PCI with a new generation drug-eluting in non-ST-elevation acute coronary syndrome…